噻唑并[5,4-c]吡啶-2-胺 | 108310-79-8

• 物质功能分类: 医药中间体 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 噻唑并[5,4-c]吡啶-2-胺
• 中文别名: 噻唑并[5,4-C]2-氨基吡啶；2-氨基-噻唑[5,4-C]吡啶；噻唑并5,4-C2-氨基吡啶
• 英文名称: thiazolo[5,4-c]pyridin-2-amine
• 英文别名: [1,3]thiazolo[5,4-c]pyridin-2-amine
• CAS: 108310-79-8
• 化学式: C₆H₅N₃S
• mdl: MFCD09909658
• 分子量: 151.192
• InChiKey: CUPNTGIGCVTGFR-UHFFFAOYSA-N

物化性质

• 沸点：
  350.3±34.0 °C(Predicted)
• 密度：
  1.485±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  80
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2934999090

反应信息

• 作为反应物：
  描述：

  噻唑并[5,4-c]吡啶-2-胺 生成 Thiazolo[5,4-c]pyridine, 2-hydrazinyl-
  参考文献：
  名称：

  摘要：

  DOI：
• 作为产物：
  描述：

  4,5,6,7-四氢噻唑[5,4-C]吡啶-2-胺 生成 噻唑并[5,4-c]吡啶-2-胺
  参考文献：
  名称：

  摘要：

  DOI：

文献信息

• APOPTOSIS-INDUCED AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES
  申请人：AbbVie Inc.

  公开号：US20130096120A1

  公开（公告）日：2013-04-18

  Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-xL proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-xL protein.

  揭示了抑制抗凋亡Bcl-xL蛋白活性的化合物，含有这些化合物的组合物以及治疗在其中表达抗凋亡Bcl-xL蛋白的疾病的方法。
• [EN] HETEROBICYCLIC CARBOXAMIDES AND USES THEREOF<br/>[FR] CARBOXAMIDES HÉTÉROBICYCLIQUES ET LEURS UTILISATIONS
  申请人：AERIE PHARMACEUTICALS INC

  公开号：WO2021050994A1

  公开（公告）日：2021-03-18

  Provided herein are heterobicyclic cyclopropanecarboxamide and heterobicyclic carboxamide compounds. In particular, provided herein are compounds that affect the function of kinases in a cell, and that are useful as therapeutic agents or with therapeutic agents. The compounds provided herein are useful in the treatment of a variety of diseases and conditions including eye diseases such as glaucoma, cardiovascular diseases, inflammatory diseases, and diseases characterized by abnormal growth, such as cancers. Also provided herein are compositions comprising heterobicyclic cyclopropanecarboxamide or heterobicyclic carboxamide compounds.

  本文提供了杂环双环丙烷羧酰胺和杂环羧酰胺化合物。特别地，本文提供的化合物影响细胞中激酶的功能，并且可用作治疗剂或与治疗剂一同使用。本文提供的化合物可用于治疗多种疾病和病况，包括眼部疾病如青光眼，心血管疾病，炎症性疾病以及以异常生长为特征的疾病，如癌症。本文还提供了含有杂环双环丙烷羧酰胺或杂环羧酰胺化合物的组合物。
• APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES
  申请人：AbbVie Inc.

  公开号：US20150072978A1

  公开（公告）日：2015-03-12

  Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-xL proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-xL protein.

  本发明涉及抑制抗凋亡Bcl-xL蛋白活性的化合物、含有该化合物的组合物以及治疗表达抗凋亡Bcl-xL蛋白相关疾病的方法。
• Discovery and Optimization of Isoquinoline Ethyl Ureas as Antibacterial Agents
  作者：Philippe Panchaud、Thierry Bruyère、Anne-Catherine Blumstein、Daniel Bur、Alain Chambovey、Eric A. Ertel、Markus Gude、Christian Hubschwerlen、Loïc Jacob、Thierry Kimmerlin、Thomas Pfeifer、Lars Prade、Peter Seiler、Daniel Ritz、Georg Rueedi

  DOI：10.1021/acs.jmedchem.6b01834

  日期：2017.5.11

  Our strategy to combat resistant bacteria consisted of targeting the GyrB/ParE ATP-binding sites located on bacterial DNA gyrase and topoisomerase IV and not utilized by marketed antibiotics. Screening around the minimal ethyl urea binding motif led to the identification of isoquinoline ethyl urea 13 as a promising starting point for fragment evolution. The optimization was guided by structure-based design and focused on antibacterial activity in vitro and in vivo, culminating in the discovery of unprecedented substituents able to interact with conserved residues within the ATP-binding site. A detailed characterization of the lead compound highlighted the potential for treatment of the problematic fluoroquinolone-resistant MRSA, VRE, and S. pneumoniae, and the possibility to offer patients an intravenous-to-oral switch therapy was supported by the identification of a suitable prodrug concept. Eventually, hERG K-channel block was identified as the main limitation of this chemical series, and efforts toward its minimization are reported.
• Iodine-catalyzed amination of benzothiazoles with KSeCN in water to access primary 2-aminobenzothiazoles
  作者：Yu-Shen Zhu、Linlin Shi、Lianrong Fu、Xiran Chen、Xinju Zhu、Xin-Qi Hao、Mao-Ping Song

  DOI：10.1016/j.cclet.2021.08.070

  日期：2022.3